Plus: COVID-19 vaccine errors and resolutions; more
Tuesday, Jan. 19, 2021 : Issue #1099 DISASTERS AVERTED — Near Miss Case Studies
Errors and Resolutions in the Use of the COVID-19 Vaccine |
|
Letter from the Editor
There is no doubt that some companies are benefiting from the current pandemic. I am not saying they are gouging patients, but just that the opportunity to market products like PPE and ventilators and supplies is driving giant sales. In addition, if your company happens to have an approved virus vaccine like Pfizer, or a therapy to reduce COVID severity like Gilead, your sales will be through the roof. But what about the rest of Pharma and all the medications for chronic diseases, like hypertension or diabetes, or asthma?
We know that many patients are either stretching their medications or stopping them all together. This has evidently had an effect on the bottom lines of some large pharma companies. Most companies raise their prices every January, and today it was announced that drug prices for already marketed drugs had increased more than in the past 5 years, and more companies than ever announced price increases.
This all means our jobs will be a little harder, and I encourage all of you to help your patients by going the extra step to do the prior authorizations when needed, and using manufacturer buy down programs when possible.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
DISASTERS AVERTED — Near Miss Case Studies |
|
| Errors and Resolutions in the Use of the COVID-19 Vaccine
As the new vaccines for COVID-19 are rolled out, the Institute for Safe Medication Practices (ISMP) has called attention to some of the missteps in vaccine administration that have occurred, and offers safe practice recommendations. |
| |
|
|
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| | | | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
